Resultados de Búsqueda

NICE

NICE

Valproate should not be initiated in people under 55 years of age, regardless of sex, unless two specialists independently agree and document that no other effective and tolerated treatment is available, or there are compelling reasons why reproductive risks do not apply. For men already taking valproate, effective contraception should be recommended throughout treatment and for at least three months after discontinuation. Men planning to conceive within the next year should be informed about ...

NICE

NICE

NICE recommends not to routinely perform follow‑up chest X‑rays in people discharged after an episode of pneumonia, as current evidence does not show meaningful clinical benefit for most patients and routine imaging may lead to unnecessary investigations. The committee reviewed studies with variable risk of bias, showing malignancy detection rates between 0.6% and 3.8%, with higher diagnostic yield in older adults, smokers, and those with underlying respiratory disease. Most residual ...

NICE

NICE

NICE recommends not to routinely use urinary antigen tests in children and young people with severe community‑acquired pneumonia (CAP), as available evidence is very limited, of low applicability, and provides uncertain diagnostic value in guiding treatment decisions. The committee reviewed very low‑certainty evidence suggesting a possible association between strongly positive urinary antigen tests and outcomes such as ICU admission or need for ventilation; however, these findings ...

NICE

NICE

NICE recommends not to routinely perform microbiological tests (cultures, PCR or pathogen‑specific assays) in adults with low‑severity community‑acquired pneumonia (CAP) or children with non‑severe CAP, as available evidence does not demonstrate meaningful clinical benefit and may introduce unnecessary delays. The committee reviewed prognostic studies and recent test‑and‑treat trials showing that PCR testing may increase pathogen‑directed therapy but does not affect mortality, ...

NICE

NICE

NICE recommends not to routinely use single-step scaffold insertion for the treatment of symptomatic chondral knee defects, except under standard arrangements for clinical governance, informed consent, and outcome auditing. Current evidence shows short- and mid‑term efficacy and safety, with improvements in pain, joint function, and cartilage regeneration over 12 to 36 months. Reported graft survival is high, with low rates of major complications. Although the procedure is already ...